SCHEMBL17985643

SCHEMBL17985643

Cc1cc(NCCCN(C)C)nc(NC(=N)Nc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DNM2 P50570 7/20 0.46
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
STK17A Q9UEE5 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LCK P06239 1/20 0.37
RAC1 P63000 1/20 0.36
HTR2C P28335 1/20 0.36
MCHR2 Q969V1 1/20 0.36
MCHR1 Q99705 1/20 0.36
MAPT P10636 1/20 0.36
APEX1 P27695 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18017317 0.93 DNM2 (0.45) DNM2ALDH1A1LMNATP53TSHR
SCHEMBL17985674 0.91 STK17A (0.39) DNM2NPC1RAB9ASTK17AALDH1A1
SCHEMBL29486340 0.88 NPC1 (0.52) DNM2NPC1RAB9ALMNAHTT
SCHEMBL29486342 0.88 NPC1 (0.52) DNM2NPC1RAB9ALMNAHTT
SCHEMBL29349616 0.88 NPC1 (0.52) DNM2NPC1RAB9ALMNAHTT
SCHEMBL18053805 0.88 NPC1 (0.52) DNM2NPC1RAB9ALMNAHTT
SCHEMBL17985641 0.88 DNM2 (0.46) DNM2NPC1RAB9AALDH1A1LMNA
SCHEMBL29486341 0.88 NPC1 (0.52) DNM2NPC1RAB9ALMNAHTT
SCHEMBL18017339 0.86 DNM2 (0.44) DNM2NPC1RAB9ASTK17AALDH1A1
SCHEMBL17985656 0.86 DNM2 (0.44) DNM2NPC1RAB9ASTK17AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227333-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2019-03-12 US disclosed
US-10227333-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2019-03-12 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227333-B2 Inhibition of OLIG2 activity GLI2, ING2, GMFG DNM2 736/4885NPC1 4224/4885RAB9A 3638/4885
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG DNM2 736/4885NPC1 4224/4885RAB9A 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.